Stay updated on Psilocybin vs Escitalopram for MDD Clinical Trial
Sign up to get notified when there's something new on the Psilocybin vs Escitalopram for MDD Clinical Trial page.

Latest updates to the Psilocybin vs Escitalopram for MDD Clinical Trial page
- Check3 days agoChange DetectedThe page no longer displays the 403 error text, study/search breadcrumbs, or an NIH announcement banner. The remaining view shows the site navigation and footer.SummaryDifference2%

- Check10 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check17 days agoChange DetectedA banner announces an NIH website transition and says the term “Super Intelligence” may appear in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check24 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check31 days agoChange DetectedThe site footer revision advanced from v3.7.0 to v3.7.1; the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check52 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record with a standard error page and blocking access to the trial details. This effectively hides core content that users rely on to view the study information.SummaryDifference19%

Stay in the know with updates to Psilocybin vs Escitalopram for MDD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Psilocybin vs Escitalopram for MDD Clinical Trial page.